<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016482</url>
  </required_header>
  <id_info>
    <org_study_id>M13-674</org_study_id>
    <secondary_id>2013-003275-36</secondary_id>
    <nct_id>NCT02016482</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis</brief_title>
  <official_title>A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety and efficacy of adalimumab in subjects
      with nail psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects achieving a total-fingernail modified Nail Psoriasis Severity Index (mNAPSI) 75 response</measure>
    <time_frame>At Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects achieving a 75% reduction in total mNAPSI of all fingernails</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For US regulatory purposes: Proportion of subjects with a Physician's Global Assessment of Fingernails of &quot;clear&quot; or &quot;minimal&quot;</measure>
    <time_frame>At Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's fingernails that meet definition of clear or minimal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For Ex-US sites: Percent change in total mNAPSI of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Ex-US: Proportion of subjects achieving mNAPSI = 0 in all fingernails</measure>
    <time_frame>At Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who achieve a mNAPSI score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Ex-US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Ex-US: Change in Nail Psoriasis Physical Functioning Severity Score</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Ex-US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with 50% improvement in the scalp component among subjects with scalp score of 6 or greater at Week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Ex-US: Proportion of subjects achieving Physician's Global Assessment of Fingernails (PGA-F) of &quot;Clear&quot; or &quot;minimal&quot;</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Proportion of subjects acheiving a total mNAPSI 75 response</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with at least a 75% reduction in total mNAPSI of all fingernails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Percent change in total mNAPSI of all fingernails</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Proportion of subjects achieving mNAPSI = 0 in all fingernails</measure>
    <time_frame>At Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects mNAPSI = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Change in Nail Psoriasis Physical Functioning Severity Score</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with 50% improvement in the scalp component among subjects with scalp score of 6 or greater at Week 0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving a total-fingernail mNAPSI 75 response</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with a 75% improvement in mNAPSI score</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving PGA-F of &quot;clear&quot; or &quot;minimal&quot;</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's fingernails that meet definition of clear or minimal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving &quot;clear&quot; or &quot;minimal&quot; in nail bed component of the PGA-F, among those with a nail bed component of &quot;moderate&quot; or worse.</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's fingernails that meet definition of clear or minimal among those with a nail bed component of &quot;moderate&quot; for worse.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving &quot;clear&quot; or &quot;minimal&quot; in nail matrix component of the PGA-F, among those with a nail matrix component of &quot;moderate&quot; or worse.</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's fingernails that meet definition of clear or minimal among those with a nail matrix component of &quot;moderate&quot; or worse.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving mNAPSI = 0 in target fingernail.</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving mNAPSI = 0 of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving mNAPSI ≤ 2 of the target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving mNAPSI ≤ 2 of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in mNAPSI of the target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in mNAPSI score of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving NAPSI=0 in all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving NAPSI=0 in target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in total NAPSI of of target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in total NAPSI of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving total PASI 75/50/90/100 among subjects with PASI score ≥ 5</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving physician's global assessment of skin psoriasis (PGA-S) &quot;clear&quot; or &quot;minimal&quot;</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's skin psoriasis that meets definition of clear or minimal</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total body surface area (BSA)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Nail Psoriasis Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Nail Psoriasis Physical Functioning Severity Score</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in dermatology life quality index (DLQI)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving DLQI of 0, and achieving DLQI of 0/1</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in EuroQol-5Dimensions-5Levels (EQ-5D-5L) Health Status Assessment</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects with a new diagnosis of psoriatic arthritis (PsA) during the study (with adverse event of PsA) among subjects without PsA.</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Nail Psoriasis Quality of Life (Nail PsQoL)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in mNAPSI of the target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in mNAPSI score of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in total NAPSI of target fingernail</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in total NAPSI of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Psoriasis Area Severity Index (PASI) of all fingernails</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in total body surface area (BSA)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Nail Psoriasis Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Nail Psoriasis Physical Functioning Severity Score</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects acheiving PGA-F of &quot;clear&quot;</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's fingernails that meet definition of clear</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects acheiving PGA-S of &quot;clear&quot;</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's assessment of patient's skin psoriasis that meets definition of clear</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects achieving 50% improvement in the scalp component of Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with 50% improvement in the scalp component of the B-SNIPI among subjects with scalp score of 6 and greater at Week 0</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects acheiving 50% improvement in inverse psoriasis component of the B-SNIPI</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects achieving 50% improvement in inverse psoriasis component among subjects with inverse psoriasis score of 6 and greater at Week 0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nail Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Adalimumab (ADA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab (ADA) sc eow (subcutaneous every other week) starting 1 week after initial loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO) Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PBO) Arm:  Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab (ADA)</intervention_name>
    <description>Adalimumab (ADA)</description>
    <arm_group_label>Adalimumab (ADA)</arm_group_label>
    <arm_group_label>Placebo (PBO) Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (PBO) Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects with clinical diagnosis of chronic plaque psoriasis (with a disease
             duration of at least 6 months) and at least 1 fingernail with nail psoriasis.

          -  Subject must have BSA ≥ 10% and a target fingernail mNAPSI ≥ 8 at Week 0, OR BSA ≥
             5%, a target fingernail mNAPSI ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0.

          -  Subject must have a Nail Psoriasis Physical Functioning Severity score of &gt; 3, OR a
             Nail Psoriasis Pain NRS score of &gt;3.

          -  Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and
             a PGA of Skin Psoriasis of at least moderate.

          -  Subject must have discontinued use of all systemic therapies for the treatment of
             psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks
             prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to
             Week 0.

          -  Target fingernail must have mNAPSI score of ≥ 8.

          -  Adult subjects with clinical diagnosis of chronic.

        Exclusion Criteria:

          -  Prior adalimumab therapy.

          -  Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or
             viral) that may interfere with evaluation of skin or fingernail psoriasis.

          -  Recent infection requiring treatment.

          -  Significant medical events or conditions that may put patients at risk for
             participation, including recent history of drug or alcohol abuse.

          -  Female subjects who are pregnant or breast-feeding or considering becoming pregnant
             during the study.

          -  History of cancer, except successfully treated skin cancer.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn  M Carlson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah K Maddux, BS</last_name>
    <phone>847-937-2178</phone>
    <email>sarah.maddux@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>La'Cheir S Hopkins, BS</last_name>
    <phone>847-935-6434</phone>
    <email>lacheir.hopkins@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116745</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116745</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116741</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116741</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116884</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116884</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116750</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116750</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116772</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116772</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116797</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116797</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119597</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119597</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116771</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116771</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116747</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116747</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118075</name>
      <address>
        <city>Carlton</city>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118075</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118076</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118076</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116495</name>
      <address>
        <city>Phillip</city>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116495</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116515</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116515</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 122415</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 122415</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118096</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118096</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116516</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116516</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117977</name>
      <address>
        <city>Markham</city>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 117977</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117980</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 117980</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117979</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 117979</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120395</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120395</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116536</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116536</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116636</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116636</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117983</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 117983</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120777</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120777</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116640</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116640</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116642</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116642</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117985</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 117985</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118863</name>
      <address>
        <city>Monterrey</city>
        <zip>CP 64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118863</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118865</name>
      <address>
        <city>Zapopan</city>
        <zip>CP 45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118865</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116720</name>
      <address>
        <city>Carolina</city>
        <zip>00985</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116720</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Nail Psoriasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
